Conference
Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The innovate clinical development program
Authors
Mian H; Touzeau C; Holstein S; Kingsley E; Vogl D; Zuniga R; Kim K; Suryanarayan K; Wang S; Thesillat-Versmee L
Volume
23
Pagination
pp. S147-S147
Publisher
CIG MEDIA GROUP, LP
Publication Date
9 2023
Conference proceedings
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
ISSN
2152-2650